Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy

被引：0

作者：

James W. Wheless

Dennis Dlugos

Ian Miller

D. Alexander Oh

Neha Parikh

Steven Phillips

J. Ben Renfroe

Colin M. Roberts

Isra Saeed

Steven P. Sparagana

Jin Yu

Maria Roberta Cilio

机构：

[1] University of Tennessee Health Science Center,Doernbecher Childhood Epilepsy Program, Department of Pediatrics

[2] Le Bonheur Children’s Hospital,UCSF Benioff Children’s Hospital

[3] Children’s Hospital of Philadelphia,Saint

[4] Perelman School of Medicine at the University of Pennsylvania,Luc University Hospital

[5] Nicklaus Children’s Hospital,undefined

[6] INSYS Development Company,undefined

[7] Inc.,undefined

[8] Mary Bridge Children’s Neurology Clinic,undefined

[9] Child Neurology Center of Northwest Florida,undefined

[10] Oregon Health and Science University,undefined

[11] University of California San Francisco,undefined

[12] Texas Scottish Rite Hospital for Children,undefined

[13] University of Louvain,undefined

[14] Arena Pharmaceuticals,undefined

来源：

CNS Drugs | 2019年 / 33卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：593 / 604

页数：11

共 27 条

[1] Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy
Wheless, James W.
Dlugos, Dennis
Miller, Ian
Oh, D. Alexander
Parikh, Neha
Phillips, Steven
Ben Renfroe, J.
Roberts, Colin M.
Saeed, Isra
Sparagana, Steven P.
Yu, Jin
Cilio, Maria Roberta
Kohrman, Michael
Raja, Roshan
CNS DRUGS, 2019, 33 (06) : 593 - 604
[2] Cannabidiol in patients with treatment-resistant epilepsy
Mandelbaum, David E.
LANCET NEUROLOGY, 2016, 15 (06): : 544 - 545
[3] Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy
Davis, Brittney H.
Beasley, T. Mark
Amaral, Michelle
Szaflarski, Jerzy P.
Gaston, Tyler
Grayson, Leslie Perry
Standaert, David G.
Bebin, E. Martina
Limdi, Nita A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1368 - 1380
[4] Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol
Kenyon, Julian
Liu, Wai
Dalgleish, Angus
ANTICANCER RESEARCH, 2018, 38 (10) : 5831 - 5835
[5] Cannabidiol in patients with treatment-resistant epilepsy Reply
Devinsky, Orrin
Marsh, Eric
Friedman, Daniel
LANCET NEUROLOGY, 2016, 15 (06): : 545 - 546
[6] Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy
Kim, Se Hee
Choi, Han Som
Koo, Chung Mo
Joo, Bong-Rim
Park, Byung-Joo
Lee, Hae Kook
Lee, Joon Soo
Kim, Heung Dong
Kang, Hoon-Chul
JOURNAL OF CLINICAL NEUROLOGY, 2022, 18 (05): : 547 - 552
[7] Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy
Metternich, Birgitta
Wagner, Kathrin
Geiger, Maximilian J.
Hirsch, Martin
Schulze-Bonhage, Andreas
Klotz, Kerstin A.
EPILEPSY & BEHAVIOR, 2021, 114
[8] The longitudinal effects of cannabidiol on brain temperature in patients with treatment-resistant epilepsy
Sharma, Ayushe A.
Szaflarski, Jerzy P.
EPILEPSY & BEHAVIOR, 2024, 151
[9] Combined vagus nerve stimulation and cannabidiol in patients with treatment-resistant epilepsy
Bezerra, D.
Meira, I.
Cukiert, C.
Goes, F.
Lessa, V.
Martins, M.
EPILEPSIA, 2024, 65 : 493 - 494
[10] Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, Orrin
Marsh, Eric
Friedman, Daniel
Thiele, Elizabeth
Laux, Linda
Sullivan, Joseph
Miller, Ian
Flamini, Robert
Wilfong, Angus
Filloux, Francis
Wong, Matthew
Tilton, Nicole
Bruno, Patricia
Bluvstein, Judith
Hedlund, Julie
Kamens, Rebecca
Maclean, Jane
Nangia, Srishti
Singhal, Nilika Shah
Wilson, Carey A.
Patel, Anup
Cilio, Maria Roberta
LANCET NEUROLOGY, 2016, 15 (03): : 270 - 278

← 1 2 3 →